banner
 
bar

program

slides

  test

syllabus
bar
 
 

Optimizing Neurotherapy and Emerging Paradigms in Alzheimer’s Disease

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period August 15, 2010 through August 15, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

2.5 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the diagnosis and management of Alzheimer’s disease.

Release Date:

August 15, 2010

Expiration Date:

August 15, 2012

Intended Audience:

This complimentary CME educational activity is designed for all physicians, academicians, researchers, investigators, support staff, nurses, and program directors from the fields of neurology, primary care, geriatric medicine, internal medicine and psychiatry, as well as those with a special interest in Alzheimer’s disease.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

EisaiSupported by an independent
educational grant from
Eisai, Inc

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

PROGRAM CHAIRMAN
Murray A. Raskind, MD – Program Chairman
Professor and Vice-Chairman
Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Director of the University of Washington Alzheimer's Disease Research Center
Director of Mental Health Service
VA Puget Sound Health Care System
Director of the VA Northwest Network Mental Illness Research, Education and Clinical Center (MIRECC)

Consultant and grant/research support: Elan/Janssen


Sandra E. Black, MD, FRCPC
Brill Chair in Neurology
University of Toronto,
Sunnybrook Health Sciences Centre
Toronto, Ontario
Canada

Consultant: Pfizer/Wyeth, Janssen-Ortho, BMS
Speaker’s Bureau: Eisai, Pfizer, Novartis, Janssen-Ortho
Grant/Research Support: Pfizer, Roche, Wyeth, Novartis



James E. Galvin, MD, MPH
Professor of Neurology and Psychiatry
Director of Clinical Operations
Center of Excellence on Brain Aging Director
Pearl Barlow Center for Memory Evaluation and Treatment
New York University Langone School of Medicine
New York, NY

Consultant: Pfizer, Eisai, Novartis, Medivation
Speaker’s Bureau: Pfizer, Novartis, Forest
Grant/Research Support: Elan, Wyeth, Novartis, Lilly




Serge Gauthier, MD
Director of the Alzheimer's Disease Research Unit
McGill Centre for Studies in Aging
Professor of Neurology and Neurosurgery, Psychiatry and Medicine
McGill University
Montreal, Quebec

Consultant: Pfizer, Novartis, Janssen, Lundbeck

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewers Denise Leary and Richard Aghababian, MD have nothing to disclose.

Educational Objectives:

After completing this activity, the participant should be able to:

  • Apply national association and expert-based guidelines for agents indicated for moderate or severe AD
  • Understand the scientific basis and the role of abnormalities in cholinergic transmission as one of the pathophysiological underpinnings responsible for symptoms in AD
  • Understand the clinical implications of current investigations focused on evolving biomarkers and their implications for early, preclinical diagnosis of AD
  • Detail the pathophysiology of AD, and the implications for current and evolving therapies of AD
  • Discuss the potential role of neuroimaging techniques to diagnose and monitor clinical progress of patients with AD

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer:

Copyright © 2011 Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides

  test

syllabus
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved.


 
6

 

Key Program Topics Include:

Acetylcholine
Acetylcholinesterase Inhibitors
ADNI
Alzheimer’s Disease
biomarkers
amyloid
Amyloid Hypothesis
anti-amyloid
anti-beta-amyloid

APP mutations
Aripiprazole

Bapineuzumab
beta-amyloid
Cholinergic Hypothesis
cholinesterase
Cholinesterase Inhibitor
cholinesterases

CSF Biomarker
CSF Norepinephrine
donepezil,
Galantamine
Ligands
MCI
Memantine
Neuroimaging Initiative
Olanzapine
PET imaging
PIB
Pittsburgh Compound B
Prazosin
Quetiapine
Risperidone
Rivastigmine
Solanezumab
tau concentrations
vitamin E